Clarity Pharmaceuticals Says Phase 2 Prostate Cancer Imaging Trial Completes Enrollment; Shares Rise 3%

MT Newswires Live

Jul 17, 2025

Clarity Pharmaceuticals (ASX:CU6) said a prospective, investigator-initiated, phase 2 imaging trial seeking to compare the detection rate of sites of prostate cancer recurrence as determined by the number of lesions per patient, between two agents, completed enrollment, and all participants were imaged, according to a Thursday Australian bourse filing.

The study is evaluating the performance of copper-64 SAR-bisPSMA in comparison with the standard-of-care gallium-68-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA), who are candidates for curative salvage therapy.

Eligible patients were required to have had a radical prostatectomy with no salvage therapy and a PSA of between 0.2 nanograms per milliliter and 0.75 ng/mL.

The drugmaker's shares rose past 3% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2552617758"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552617758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552617758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 11:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552617758","market":"sh","top_or_hot":-1,"title":"Clarity Pharmaceuticals Says Phase 2 Prostate Cancer Imaging Trial Completes Enrollment; Shares Rise 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) said a prospective, investigator-initiated, phase 2 imaging trial seeking to compare the detection rate of sites of prostate cancer recurrence as determined by the number of lesions per patient, between two agents, completed enrollment, and all participants were imaged, according to a Thursday Australian bourse filing.</p><p>The study is evaluating the performance of copper-64 SAR-bisPSMA in comparison with the standard-of-care gallium-68-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA), who are candidates for curative salvage therapy.</p><p>Eligible patients were required to have had a radical prostatectomy with no salvage therapy and a PSA of between 0.2 nanograms per milliliter and 0.75 ng/mL.</p><p>The drugmaker's shares rose past 3% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals Says Phase 2 Prostate Cancer Imaging Trial Completes Enrollment; Shares Rise 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals Says Phase 2 Prostate Cancer Imaging Trial Completes Enrollment; Shares Rise 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-17 11:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) said a prospective, investigator-initiated, phase 2 imaging trial seeking to compare the detection rate of sites of prostate cancer recurrence as determined by the number of lesions per patient, between two agents, completed enrollment, and all participants were imaged, according to a Thursday Australian bourse filing.</p><p>The study is evaluating the performance of copper-64 SAR-bisPSMA in comparison with the standard-of-care gallium-68-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA), who are candidates for curative salvage therapy.</p><p>Eligible patients were required to have had a radical prostatectomy with no salvage therapy and a PSA of between 0.2 nanograms per milliliter and 0.75 ng/mL.</p><p>The drugmaker's shares rose past 3% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2552617758","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552617758","pubTimestamp":1752722106,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clarity Pharmaceuticals  said a prospective, investigator-initiated, phase 2 imaging trial seeking to compare the detection rate of sites of prostate cancer recurrence as determined by the number of lesions per patient, between two agents, completed enrollment, and all participants were imaged, according to a Thursday Australian bourse filing.The study is evaluating the performance of copper-64 SAR-bisPSMA in comparison with the standard-of-care gallium-68-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen , who are candidates for curative salvage therapy.Eligible patients were required to have had a radical prostatectomy with no salvage therapy and a PSA of between 0.2 nanograms per milliliter and 0.75 ng/mL.The drugmaker's shares rose past 3% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4084":"特种房地产投资信托","BK4217":"自存仓储房地产信托","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4588":"碎股","BK7096":"制药","PSA":"公共存储公司","CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"Clarity Pharmaceuticals表示2期前列腺癌成像试验完成入组；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSA":1,"CU6.AU":0.9},"content_text":"Clarity Pharmaceuticals (ASX:CU6) said a prospective, investigator-initiated, phase 2 imaging trial seeking to compare the detection rate of sites of prostate cancer recurrence as determined by the number of lesions per patient, between two agents, completed enrollment, and all participants were imaged, according to a Thursday Australian bourse filing.The study is evaluating the performance of copper-64 SAR-bisPSMA in comparison with the standard-of-care gallium-68-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA), who are candidates for curative salvage therapy.Eligible patients were required to have had a radical prostatectomy with no salvage therapy and a PSA of between 0.2 nanograms per milliliter and 0.75 ng/mL.The drugmaker's shares rose past 3% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}